StreetInsider.com News Articles

bioAffinity Technologies sets 1-for-15 reverse stock split Aug. 24

Thu, 20 Aug 2026 08:00:23 -0400

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.

The reverse stock split was approved by stockholders at the company's annual meeting on April 30, 2026. The split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement.

Following the split, every 15 shares of issued and outstanding common stock will be exchanged for one share. The company will have approximately 592,373 shares of common stock issued and outstanding after the split takes effect. Stockholders who

bioAffinity Technologies sets 1-for-15 reverse stock split Aug. 24

Thu, 20 Aug 2026 08:00:23 -0400

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.

bioAffinity Technologies sets 1-for-15 reverse stock split Aug. 24

Thu, 20 Aug 2026 08:00:23 -0400

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026.

As a result of the reverse

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

As a result of the reverse

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

As a result of the reverse

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

As a result of the reverse

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

As a result of the reverse

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

Thu, 20 Aug 2026 08:00:00 -0400

As a result of the reverse

bioAffinity strikes federal distribution deal for CyPath Lung test

Tue, 18 Aug 2026 08:01:26 -0400

bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, to market its CyPath Lung diagnostic test to federal healthcare agencies, including U.S. Department of Veterans Affairs medical centers nationwide.

Under the agreement, AvMEDICAL's sales team will promote CyPath Lung to its federal government customers, and the two companies will develop co-branded marketing materials. AvMEDICAL's access to indefinite-delivery, indefinite-quantity contracts is expected to simplify the procurement process within government healthcare systems.

CyPath Lung is a noninvasive test that uses flow cytometry and artificial intelligence to analyze patient sputum for cell populations indicating malignancy.

bioAffinity strikes federal distribution deal for CyPath Lung test

Tue, 18 Aug 2026 08:01:26 -0400

CyPath Lung is a noninvasive test that uses flow cytometry and artificial intelligence to analyze patient sputum for cell populations indicating malignancy.

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

Tue, 18 Aug 2026 08:00:00 -0400